A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is ...

Daiichi Sankyo used the National Cherry Blossom Festival in Washington, D.C. as a platform to raise awareness about its oncology goals.

Trastuzumab deruxtecan approved to treat adults with HER2-positive cancer that’s spread or can’t be removed by surgery.

A brave gran battling breast cancer for more than a decade is facing the heart-wrenching prospect of moving hundreds of miles to Scotland for access to a drug that could save her life. Beverley Angell ...

A grandma who has fought breast cancer for more than a decade may be forced to move to Scotland to access a lifesaving drug.

Beverley Angell, 68, is having to consider moving 467 miles from London to Scotland as the drug she needs - Enhurtu for HER2-low - is not available on the NHS in England. Privately it would cost ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, ...

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

A new drug that helps slow the spread of an incurable type of breast cancer has been approved for use in Britain's state-run ...

The global Breast Cancer Diagnostics Market is valued at USD 19.43 Billion in 2024 and is projected to reach a value of USD ...

Breast cancer remains the most common cancer among women globally, and Germany stands at the forefront of offering advanced and effective treatment options. Through a combination of high medical ...